ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study

  • ATAI Life Sciences NV ATAI announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS).
  • Related Link: Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company. 
  • Data demonstrated potential pro-cognitive effects of RL-007, a cholinergic, glutamatergic, and GABA type B receptor modulator. 
  • After this early data, ATAI will commit additional financial resources for the accelerated development of RL-007.
  • The interim Phase 2a readout reported promising assessments from two quantitative biomarkers, qEEG (quantitative electroencephalogram) and ERP (evoked-response potential), and indicated changes consistent with improved cognition. 
  • Full results of the current Phase 2a trial are expected by the end of 2021.
  • Related: Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial.
  • Price Action: ATAI shares closed 6.37% higher at $15.52 on Monday.
Loading...
Loading...
ATAI Logo
ATAIATAI Life Sciences NV
$1.62-0.50%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
59.95
Growth
-
Quality
-
Value
1.25
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...